E
Erling Tjora
Researcher at Haukeland University Hospital
Publications - 47
Citations - 1119
Erling Tjora is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Pancreas & Medicine. The author has an hindex of 15, co-authored 34 publications receiving 888 citations. Previous affiliations of Erling Tjora include University of Bergen.
Papers
More filters
Journal ArticleDOI
A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis
Karianne Fjeld,Frank Ulrich Weiss,Denise Lasher,Jonas Rosendahl,Jian-Min Chen,Jian-Min Chen,Bente B. Johansson,Bente B. Johansson,Holger Kirsten,Claudia Ruffert,Emmanuelle Masson,Solrun J. Steine,Peter Bugert,Miriam Cnop,Robert Grützmann,Julia Mayerle,Joachim Mössner,Monika Ringdal,Monika Ringdal,Hans-Ulrich Schulz,Matthias Sendler,Peter Simon,Paweł Sztromwasser,Paweł Sztromwasser,Janniche Torsvik,Janniche Torsvik,Markus Scholz,Erling Tjora,Erling Tjora,Claude Férec,Heiko Witt,Markus M. Lerch,Pål R. Njølstad,Pål R. Njølstad,Stefan Johansson,Stefan Johansson,Anders Molven,Anders Molven +37 more
TL;DR: A hybrid allele (CEL-HYB) originating from a crossover between CEL and its neighboring pseudogene, CELP is described, implicate a new pathway distinct from the protease-antiprotease system of pancreatic acinar cells in chronic pancreatitis.
Journal ArticleDOI
Derivation of Human Induced Pluripotent Stem Cells from Patients with Maturity Onset Diabetes of the Young
Adrian Kee Keong Teo,Rebecca Windmueller,Bente B. Johansson,Bente B. Johansson,Ercument Dirice,Pål R. Njølstad,Erling Tjora,Helge Ræder,Rohit N. Kulkarni +8 more
TL;DR: The derivation of human induced pluripotent stem cells (hiPSCs) from patients with five types of MODY are reported, for the first time, to serve as invaluable tools to dissect the role of MODy genes in the development of pancreas and islet cells and to evaluate their significance in regulating beta cell function.
Journal ArticleDOI
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Pamela Bowman,Åsta Sulen,Åsta Sulen,Fabrizio Barbetti,Jacques Beltrand,Pernille Svalastoga,Pernille Svalastoga,Ethel Codner,Ellen H Tessmann,Petur Benedikt Juliusson,Petur Benedikt Juliusson,Torild Skrivarhaug,Ewan R. Pearson,Sarah E. Flanagan,Tarig Babiker,Nicholas J. Thomas,Maggie Shepherd,Sian Ellard,Iwar Klimes,Magdalena Szopa,Michel Polak,Dario Iafusco,Andrew T. Hattersley,Pål R. Njølstad,Pål R. Njølstad,Javier Aisenberg,Ilker Akkurt,Hussein Abdul-Latif,Anees Al-Abdullah,L Barak,Joop P. W. van den Bergh,Anne-Marie Bertrand,Carla Bizzarri,Riccardo Bonfanti,Henri Bruel,Anthony Burrows,Francesco Cadario,Fergus J. Cameron,Dennis Carson,Maryse Cartigny,Vittoria Cauvin,Hélène Cavé,Ali J. Chakera,Ravi Chetan,Giovanni Chiari,Bob Couch,Régis Coutant,Elizabeth Cummings,Adriana Dankovcikova,Liz Davis,Dorothee Deiss,Maurizio Delvecchio,Elena Faleschini,Anne-Laure Fauret,Roisin Finn,Tamsin Ford,Elisa De Franco,Bastian De Gallen,Daniela Gasperikova,Padma Guntamukkala,Vaseem Hakeem,Shinji Hasegawa,Eba Hathout,Emmeline Heffernan,David Hill,Josephine Ho,Marie Hoarau,Reinhard W. Holl,Rebecca Hoddinott,Jane Houghton,Neville J. Howard,Natalie Hughes,Ian Hunter,Anne Kirsti Høgåsen,Helena Kuulasmaa,Sorin Ioacara,Violeta Iotova,Henrik Irgens,Alan Jaap,Kenneth Jones,Thomas Kapellen,Ellen Kaufman,Andreas Klinge,Tomasz Klupa,Ramaiyer Krishnaswamy,Tony Lafferty,Laurent Legault,Paul Lambert,Maciej T. Malecki,Olag Malievsky,Revi Mathew,Frances Mathews,Robert McVie,Ulrike Menzel,Chantale Metz,John Van Der Meulen,Gita Modgil,Dick Mul,Silvia Muther,Roos Nuboer,Susan M. O’Connell,Stephen Mp O’Riordan,Miroslav Palko,Kashyap A. Patel,Roberta Pesavento,Elvira Piccinno,Janani Kumaraguru Pillai,Stephanka Pruhova,Zubin Punthakee,Ivana Rabbone,Klemens Raile,Marielisa Rincon,Danette Rose,Janine Sanchez,Susan Sandereson,Vinay Saxena,Martin Schebek,Dorothee Schmidt,Naim Shehadeh,Julian P.H. Shiels,Jose M. C. L Silva,Juraj Stanik,Tracy Tinklin,Erling Tjora,Stefano Tumini,Tiinamaija Tuomi,Akiko Uehara,Robert Y. van der Velde,Guido Vermeulen,Uma Visser,Paul Voorhoeve,Jan L Walker,Jaques Weill,Tobias Weisner,Andrea Werner,Toni Williams,Helen J Woodhead,Rønnaug øddegård +137 more
TL;DR: Ten-year multicentre follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes to address the key questions relating to long-term efficacy and safety of sulfonylureas in these patients, with main outcomes of interest sulfONYlurea failure, defined as permanent reintroduction of daily insulin, and metabolic control, specifically HbA1c and sulfonyLurea dose.
Journal ArticleDOI
A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Gaya Thanabalasingham,Gaya Thanabalasingham,Nida Shah,Martine Vaxillaire,Torben Hansen,Torben Hansen,Tiinamaija Tuomi,Daniela Gasperikova,Magdalena Szopa,Erling Tjora,Erling Tjora,Tim James,P. Kokko,F. Loiseleur,Ehm A. Andersson,Stefan Gaget,Bo Isomaa,Natalia Nowak,Helge Ræder,Helge Ræder,Juraj Stanik,Juraj Stanik,Pål R. Njølstad,Pål R. Njølstad,Maciej T. Malecki,Iwar Klimes,Leif Groop,Leif Groop,Oluf Pedersen,Philippe Froguel,Philippe Froguel,Mark I. McCarthy,Mark I. McCarthy,Anna L. Gloyn,Anna L. Gloyn,Katharine R. Owen +35 more
TL;DR: In the largest study to date, hsCRP is a clinically valid biomarker for HNF1A-MODY in European populations and could translate rapidly into clinical practice, considerably improving diagnosis rates in monogenic diabetes.
Journal ArticleDOI
Mutations in HNF1A result in marked alterations of plasma glycan profile.
Gaya Thanabalasingham,Jennifer E. Huffman,Jayesh J. Kattla,Mislav Novokmet,Igor Rudan,Igor Rudan,Anna L. Gloyn,Anna L. Gloyn,Caroline Hayward,Barbara Adamczyk,Rebecca M. Reynolds,Ana Muzinic,Neelam Hassanali,Maja Pučić,Amanda J. Bennett,Abdelkader Essafi,Ozren Polasek,S A Mughal,S A Mughal,Irma Redzic,Dragan Primorac,Dragan Primorac,Lina Zgaga,Ivana Kolcic,Torben Hansen,Torben Hansen,Torben Hansen,Daniela Gasperikova,Erling Tjora,Erling Tjora,Mark W. J. Strachan,Trine Nielsen,Juraj Stanik,Juraj Stanik,Iwar Klimes,Oluf Pedersen,Oluf Pedersen,Pål R. Njølstad,Pål R. Njølstad,Sarah H. Wild,Ulf Gyllensten,Olga Gornik,James F. Wilson,Nicholas D. Hastie,Harry Campbell,Mark I. McCarthy,Mark I. McCarthy,Pauline M. Rudd,Katharine R. Owen,Katharine R. Owen,Gordan Lauc,Alan F. Wright +51 more
TL;DR: Glycan profiles are altered substantially in HNF1A-MODY, and the DG9-glycan index has potential clinical value as a diagnostic biomarker of H NF1A dysfunction.